[Skip to Content]
[Skip to Content Landing]
Comment & Response
June 9, 2015

Varenicline for Smoking Reduction Prior to Cessation

Author Affiliations
  • 1Department of Psychiatry, University of Alabama, Birmingham
  • 2School of Public Health, University of Alabama, Birmingham
JAMA. 2015;313(22):2284-2285. doi:10.1001/jama.2015.4972

To the Editor Dr Ebbert and colleagues1 tested the efficacy of varenicline for cessation among those willing to reduce but not quit smoking. They noted abstinence rates for the primary efficacy end point of 32.1% for the varenicline group vs 6.9% for the placebo group, with expired breath carbon monoxide levels of 10 ppm or less indicating abstinence.

First Page Preview View Large
First page PDF preview
First page PDF preview